NGeneBio to Attend BIO USA, Seeking Expansion of Asian Genomics Data Business
Partnering with Tempus AI, Roche, and Others
NGeneBio is set to participate in a global bio partnering event to expand its genomics data business and seek overseas collaboration opportunities.
On June 18, NGeneBio announced that it will attend the '2026 BIO International Convention (BIO USA),' which will be held in San Diego, United States, from June 22 to June 25.
During the event, NGeneBio will hold partnering meetings with global companies and institutions in the fields of precision medicine and artificial intelligence (AI) data. The participants will include Tempus AI, Guardant Health, Foundation Medicine, Roche, Google Cloud, and Memorial Sloan Kettering Cancer Center (MSKCC), among others.
Jenny Song, the recently appointed Chief Data Officer (CDO), will attend the event to lead discussions on collaboration with global companies. CDO Song plans to highlight the clinical value of Asian genomics data, opportunities for joint research, and data supply, presenting various partnership possibilities.
NGeneBio explained that most existing global genomics databases are centered around Western populations, which is increasing the value of Korean and Asian data. The company stated that, on the occasion of BIO USA, it aims to expand collaborations in global drug development and precision medicine based on Asian genomics data.
Hot Picks Today
KOSPI Struggles to Break 7,000 Points as Over 100 Trillion Won in Individual Investor Supply Overhang Looms
- Huawei and Xiaomi Also Raise Prices... Chinese Smartphones See Consecutive Hikes Amid Soaring Memory Costs
- Packed Crowds with “It’s So Cheap!”... Japan Travel by UK Millennials & Gen Z Surges 25% in a Year
- Taiwanese Man Threw 100 Cockroaches in Restaurant... Was It Due to Service Complaints?
- "Too Tired of Seongsu and Euljiro"... Where Are Young Adults in Their 20s and 30s Going on the Hunt for Hotspots These Days?
CDO Song stated, "Although demand for Asian genomics data is rapidly increasing in global drug development and precision medicine research, the amount of data that can actually be used in clinical settings remains limited. Through this participation, we will strive to broaden collaboration with global companies and institutions and establish NGeneBio as a key data partner."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
